Document is current
Any future updates will be listed below
-
Authors
Meguro, Satoru https://orcid.org/0000-0003-2179-5028
Johmura, Yoshikazu https://orcid.org/0000-0002-6812-9607
Wang, Teh-Wei
Kawakami, Satoshi
Tanimoto, Shota
Omori, Satotaka
Okamura, Yuki T.
Hoshi, Seiji
Kayama, Emina
Yamaguchi, Kiyoshi
Hatakeyama, Seira
Yamazaki, Satoshi https://orcid.org/0000-0003-4249-3854
Shimizu, Eigo
Imoto, Seiya
Furukawa, Yoichi https://orcid.org/0000-0003-0462-8631
Kojima, Yoshiyuki https://orcid.org/0000-0001-8000-0868
Nakanishi, Makoto https://orcid.org/0000-0002-6707-3584
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP23zf0127003h, JP23gm1410013h, JP20gm5010001s, JP20ck010655h, JP21gm6410014h)
MEXT | Japan Society for the Promotion of Science (JP20H00514, JP20K21497, JP19H05740, JP19H03431, JP20H04940)
- License Information
-
More Information
Article History
Received: 25 July 2023
Accepted: 8 August 2024
First Online: 9 September 2024
Competing interests
: M.N. is a scientific advisor and shareholder at reverSASP Therapeutics. S.Y. is a co-founder of Celaid Therapeutics. The other authors declare no competing interests.
